Monday, Apr 23 2018 | Time 21:06 Hrs(IST)
image
image image
  • MHA revises SRE scheme for NE states
  • Unnao rape: Accused BJP MLA's supporters takes out rally
  • Govt sanctions 10 Indian Reserve Battalions for NE states
  • e-Way Bill system roll out in four more states, Puducherry UT from Apr 25
  • Odisha government targets to collect Rs 3800 crore excise revenue during 2018-19
  • NPP accuses opposition Congress spreading “misinformation” campaign in run up to Williamnagar polls
  • US anti-Muslim hate crimes rose 15 pct in 2017 -advocacy group
  • Karnataka polls: BJP delegation meets EC, complains about state administration not allowing party to campaign freely
  • Non-formation of CMB: Parties in Puducherry form human chain, raise anti-BJP slogans
  • Uzbekistan to join Turkmenistan-India gas pipeline project
  • BJP wokrer arrested for sexual abuse of minor girl in express train
  • Election: He pays deposit money collected under 'one vote, a Re note'
  • 2017 recorded lowest no of insurgency incidents in NE states since 1997
  • Govt funds misuse: Yogi takes action against retired engineer
  • TMC charges opposition parties with creating obstacles for poll body to hold panchayet elections
Science Technology Share

WHO advises Dengvaxia be used only in people previously infected with dengue

WHO advises Dengvaxia be used only in people previously infected with dengue

Kolkata, Dec 14 (UNI) Following a consultation of the Global Advisory Committee on Vaccine

Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold

under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but

it should not be administered to people who have not previously been infected with dengue

virus.

This recommendation is based on new evidence communicated by the vaccine’s

manufacturer (Sanofi Pasteur), indicating an increase in incidence of hospitalization and

severe illness in vaccinated children never infected with dengue.

The WHO Global Advisory Committee on Vaccine Safety considered the company’s new

results from clinical trial data analyses. Those studies indicate that increased risk of severe

dengue disease in people who have never been infected affects about 15 per cent of the

vaccinated individuals.

The magnitude of risk is in the order of about 4 out of every 1000 seronegative patients

vaccinated who developed severe dengue disease during five years of observation. The risk

of developing severe dengue disease in non-vaccinated individuals has been calculated as

1.7 per 1000 over the same period of observation.

By contrast, for the 85 per cent who have had dengue disease before immunization, there

is a reduction of 4 cases of severe dengue per 1 000 who are vaccinated.

The possibility of risk for seronegative people was raised by WHO and published in a

position paper in July 2016: “…vaccination may be ineffective or may theoretically even increase

the future risk of hospitalized or severe dengue illness in those who are seronegative at the time

of first vaccination regardless of age."

As this risk had at that time not been seen in the age groups for which the vaccine was

licensed, WHO issued a conditional recommendation, emphasizing the use of the vaccine

in populations having been previously infected with dengue virus.

To minimize illness for seronegative vaccinated people, WHO recommends enhancing

measures that reduce exposure to dengue infection among populations where the vaccine

has already been administered.

For vaccine recipients who present with clinical symptoms compatible with dengue virus

infection, access to medical care should be expedited to allow for proper evaluation,

identification, and management of severe forms of the disease.

Dengue is a mosquito-borne flavivirus disease that has spread to most tropical and many subtropical areas. The disease is caused by four closely related viruses. There is no specific

dengue treatment and prevention is mainly limited to vector control measures. A safe and

effective dengue vaccine would therefore represent a major advance in the control of the

disease.

CYD-TDV is a live attenuated tetravalent vaccine made using recombinant DNA technology

and is administered in three phases separated by six-month intervals. It became commercially available in 2016 and is currently licensed in 19 countries.

UNI BM SJC

More News
Revised SAGE recommendation on use of dengue vaccine

Revised SAGE recommendation on use of dengue vaccine

21 Apr 2018 | 12:57 PM

Kolkata, Apr 21 (UNI) Dengue is the most frequent and rapidly spreading mosquito-borne virus
Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae.

 Sharesee more..
Mosquito-packed drones ready to join fight against Zika

Mosquito-packed drones ready to join fight against Zika

20 Apr 2018 | 7:09 PM

United Nations, Apr 20 (UNI) Robotics may soon be a critical ally in the fight against disease-spreading bugs, a United Nations agency has said after a successful test releasing sterile mosquitos from aerial drones as part of efforts to suppress the insect that spreads Zika and other diseases.

 Sharesee more..
Evidence shows banning asbestos has no negative economic impact

Evidence shows banning asbestos has no negative economic impact

20 Apr 2018 | 11:56 AM

Kolkata, Apr 20 (UNI) Sound scientific evidence shows that any exposure to asbestos fibres poses significant health risks.

 Sharesee more..
Nadda directs for comprehensive strategy to tackle leprosy, TB

Nadda directs for comprehensive strategy to tackle leprosy, TB

17 Apr 2018 | 6:47 PM

New Delhi, Apr 17 (UNI) Union Minister for Health and Family Welfare JP Nadda directed for a comprehensive strategy for addressing incidence, prevalence and surveillance aspects to eliminate leprosy at district level and reviewed Tuberculosis Control Programme on Tuesday.

 Sharesee more..
Fortis Hospital performs Double Root Translocation surgery to cure 3-year-old Kashmiri boy

Fortis Hospital performs Double Root Translocation surgery to cure 3-year-old Kashmiri boy

14 Apr 2018 | 4:32 PM

New Delhi, Apr 14 (UNI A team of doctors at Fortis Memorial Research Institute (FMRI) recently performed a rare Double Root Translocation Surgery to cure three-year Mohammed Aasim, from Safapora, Ganderbal in Jammu and Kashmir recently.

 Sharesee more..
image